Cubist has developed its suite of biosynthesis technologies which allows the cloning and expression of large fragments of DNA that encode metabolic pathways from secondary metabolite-producing microorganisms, in surrogate hosts that can be more easily cultured in the laboratory. Once cloned these pathways can then be genetically engineered to then generate recombinant strains producing novel, drug metabolites as a source for new drugs.